Evaluating naloxegol for the treatment of opioid-induced constipation

Expert Opinion on Pharmacotherapy
Marzieh DanialiMohammad Abdollahi

Abstract

Due to the increased use of opioids for pain and their abuse globally, the rate of restrictive side effects is elevating. Opioid-induced constipation (OIC) is probably the most widespread, underdiagnosed, and yet common adverse effect. Naloxegol, as an opioid antagonist, is associated with beneficial impacts in OIC. Indeed, blocking mu (μ)-opioid receptors in the gastrointestinal tract (GI) may lead to neutralization of the GI adverse events of opioids. This review is based on a PubMed and Clinicaltrials.gov search for studies undertaken over the past 20 years (2000-2020) using the following keywords: Movantik®, Moventig®, Naloxegol, Opioids, Opioid-induced constipation and Opioid antagonists. Similar to the management of functional constipation, non-pharmacological therapies are applied as the first step of the procedure. However, in most cases, laxative therpaies with or without stool softeners, which may not result in satisfactory relief are applied. In these instances, administration of prokinetic agents is recommended. Furthermore, studies have shown that the best second-line therapy option is a peripherally acting μ-opioid receptor antagonist (PAMORA), which antagonizes GI adverse events.

References

Mar 14, 2001·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·M Camilleri
Apr 20, 2001·Current Pain and Headache Reports·D M Thorpe
Jan 5, 2002·American Journal of Surgery·M Pappagallo
Aug 13, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·H U De SchepperM Camilleri
Sep 11, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·C SterniniA Kirchgessner
Sep 11, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·J D Wood, J J Galligan
Oct 20, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jonathan GonenneAlan R Zinsmeister
Dec 17, 2009·Alimentary Pharmacology & Therapeutics·R E KraichelyJ A Murray
Apr 30, 2010·Digestive Diseases and Sciences·Cornelius E J SlootsMartine De Pauw
Mar 26, 2011·Advances in Therapy·Anne Estrup Olesen, Asbjørn Mohr Drewes
May 1, 2012·International Journal of Clinical Pharmacology and Therapeutics·Kevin SmithDavid Bell
Jun 2, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lars Morten SkollerudPetter C Borchgrevink
Sep 7, 2012·Drugs·Christina BrockAsbjørn Mohr Drewes
Dec 25, 2012·Gastroenterology·Adil E BharuchaG Richard Locke
Apr 3, 2013·The American Journal of Gastroenterology·Shanti EswaranWilliam D Chey
Feb 25, 2014·International Journal of Clinical Pharmacy·Anton PottegårdJens Søndergaard
Jun 5, 2014·The New England Journal of Medicine·William D CheyJan Tack
Jun 20, 2014·Journal of Clinical Pharmacology·Khanh BuiMark Sostek
Jun 25, 2014·Expert Opinion on Investigational Drugs·Shilan MozaffariMohammad Abdollahi
Sep 15, 2014·Health Policy·Zahava R S Rosenberg-Yunger, Ahmed M Bayoumi
Sep 27, 2014·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·H I AkbaraliW L Dewey
Jun 11, 2015·Scandinavian Journal of Gastroenterology·Bishal GyawaliYuichi Ando
Nov 5, 2015·United European Gastroenterology Journal·Jan TackMark Sostek
Nov 20, 2015·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Charles E ArgoffLynn R Webster
Mar 16, 2016·Therapeutic Advances in Chronic Disease·Alfred D Nelson, Michael Camilleri
Sep 2, 2016·Therapeutic Advances in Gastroenterology·Wojciech Leppert, Jaroslaw Woron
Aug 5, 2017·Patient Preference and Adherence·Stephanie C Yoon, Heather C Bruner
Dec 22, 2017·Expert Opinion on Investigational Drugs·Shilan MozaffariMohammad Abdollahi
Mar 6, 2018·Journal of Cardiovascular Pharmacology and Therapeutics·William B WhiteRaj Tummala
Jun 6, 2018·The Lancet. Gastroenterology & Hepatology·Adam D FarmerRoberto De Giorgio
Jul 7, 2018·Expert Opinion on Pharmacotherapy·Shilan MozaffariMohammad Abdollahi
Aug 22, 2018·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Esben Bolvig MarkAsbjørn Mohr Drewes
Sep 27, 2019·Expert Opinion on Pharmacotherapy·Marzieh DanialiMohammad Abdollahi

❮ Previous
Next ❯

Citations

Aug 11, 2020·Expert Review of Gastroenterology & Hepatology·Marzieh DanialiMohammad Abdollahi
May 3, 2021·European Journal of Pharmacology·Anna CostanziniGirolamo Calò

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Review of Gastroenterology & Hepatology
Jan Tack, M Corsetti
The American Journal of Hospice & Palliative Care
Rachel JonesDavid Backstedt
© 2021 Meta ULC. All rights reserved